clement, Author at BaseLaunch

Features

“I enjoy thinking about seemingly unsolvable problems”

Andreas Plückthun continues his research where others stop: 40 employees work in his laboratory on protein engineering. Their results form the basis for three biotech…

clement09.02.2018

Features

BaseLaunch up to a solid Phase II start

BaseLaunch has officially started Phase II of its accelerator program, and four startups are receiving grants ranging from 120,000 to 250,000 Swiss francs. This non-dilutive…

clement30.01.2018

Features

Novartis steps in to grab ex-US rights to pioneering gene therapy Luxturna with $170M deal

clement26.01.2018

Features

Roivant Sciences to join BaseLaunch Accelerator as Healthcare Partner

Roivant becomes the fifth healthcare partner of BaselArea.swiss accelerator program joining Johnson & Johnson Innovation, Novartis Venture Fund, Pfizer and Roche. BaseLaunch today announced that…

clement18.01.2018

Features

clement

“I enjoy thinking about seemingly unsolvable problems”

BaseLaunch up to a solid Phase II start

Novartis steps in to grab ex-US rights to pioneering gene therapy Luxturna with $170M deal

Roivant Sciences to join BaseLaunch Accelerator as Healthcare Partner

YC Bio – new way for funding early-stage life science companies

Billionaire-backed Juvenescence primes the anti-aging pipeline pump with a $12M seed round

Roche pens neurological, developmental disorder drug discovery pact with Confo

Idorsia teams up with Roche on research

Flagship adds $618M in new funds to fuel startup mission

Roche licenses Ionis’ Antisense HD Therapy following groundbreaking trial

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us